ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
OpenAI Rejects Apple Trade Secret Theft Claims 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Milei Threatens Falkland Oil Firms With Sanctions 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
France Targets Shein, Temu With Fast-Fashion Fees 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
OpenAI Nears Astra AI Model Launch With Safety Focus 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Add as a preferred source on Google
REHOVOT, Israel and NEW YORK, March 07, 2018 -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that Steve Lisi, Chief Executive Officer, will provide a corporate overview at the 30th Annual ROTH Conference, and the 28th Annual Oppenheimer Healthcare Conference.
| 30th Annual ROTH Conference | ||
| Date: | Monday, March 12 | |
| Time: | 8:30am Pacific Time/11:30am Eastern Time | |
| Location: | Ritz Carlton, Laguna Niguel, California - BLUE Track - Salon 2 | |
| Webcast: | http://wsw.com/webcast/roth32/aitb/ | |
| Oppenheimer 28th Annual Healthcare Conference | ||
| Date: | Tuesday, March 20 | |
| Time: | 4:30pm Eastern Time | |
| Location: | Westin Grand Central Hotel, Track 3 | |
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat serious lung infections and pulmonary hypertension. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
[email protected]
Bob Yedid
LifeSci Advisors, LLC
[email protected]
(646) 597 6989
